Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.57), $0.13 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $6.86 million versus the consensus estimate of $3.24 million.

Blueprint Medicines expects that its cash, cash equivalents and investments balance will be at least $120 million at December 31, 2016. In addition, Blueprint Medicines expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into late 2017.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.